

# Thrombotics and Antithrombotics

David E. Slattery

Charles V. Pollack, Jr.

## REFERENCES

1. Ageno W, Gallus AS, Wittkowsky A, et al: Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl.): e44S, 2012. [PMID: 22315269]
2. Holbrook A, Schulman S, Witt DM, et al: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl.): e152S, 2012. [PMID: 22315259]
3. De Santo LS, Romano G, Della Corta A, et al: Mechanical aortic valve replacement in young women planning on pregnancy. Maternal and fetal outcomes under low oral anticoagulation, a pilot observational study on a comprehensive pre-operative counseling protocol. *J Am Coll Cardiol* 58: 1110, 2012. [PMID: 22421305]
4. Spyropoulos AC: Bridging therapy and oral anticoagulation: current and future prospects. *Curr Opin Hematol* 17: 444, 2010. [PMID: 20613508]
5. Kaatz S, Paje D: Update in bridging anticoagulation. *J Thromb Thrombolysis* 31: 259, 2011. [PMID: 21327504]
6. Douketis JD, Spyropoulos AC, Spencer FA, et al: Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physician Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl.): e326S, 2012. [PMID: 22315266]
7. Crowther MA, Ageno W, Garcia D, et al: Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. *Ann Intern Med* 150: 293, 2009. [PMID: 19258557]
8. Denas G, Marzot F, Offelli P, et al: Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases. *J Thromb Thrombolysis* 27: 340, 2009. [PMID: 18338109]
9. Grobler C, Callum J, McCluskey SA: Reversal of vitamin K antagonists prior to urgent surgery. *Can J Anaesth* 57: 458, 2010. [PMID: 20077167]
10. Vang ML, Hvas AM, Ravn HB: Urgent reversal of vitamin K antagonist therapy. *Acta Anaesthesiol Scand* 55: 507, 2011. Erratum in: *Acta Anaesthesiol Scand* 55: 766, 2011. [PMID: 21418150]
11. Rolfé S, Papadopoulos S, Cabral KP: Controversies of anticoagulation reversal in life-threatening bleeds. *J Pharm Pract* 23: 217, 2010. [PMID: 21507817]
12. Bhagirath VC, O'Malley L, Crowther MA: Management of bleeding complications in the anticoagulated patient. *Semin Hematol* 48: 285, 2011. [PMID: 22000094]
13. Bershady EM, Suarez JJ: Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature. *Neurocrit Care* 12: 403, 2010. [PMID: 19967567]
14. Masotti L, Di Napoli M, Godoy DA, et al: The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. *Int J Stroke* 6: 228, 2011. [PMID: 21557810]
15. Bechtel B, Nunez T, Lyon J, et al: Treatments for reversing warfarin anticoagulation in patients with acute intracranial hemorrhage: a structured literature review. *Int J Emerg Med* 4: 40, 2011. [PMID: 21740550]
16. Morris TA: New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors. *Clin Chest Med* 31: 707, 2010. [PMID: 21047577]
17. Bovio JA, Smith SM, Gums JG: Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease. *Ann Pharmacother* 45: 603, 2011. [PMID: 21540406]
18. Lee CJ, Ansell JE: Direct thrombin inhibitors. *Br J Clin Pharmacol* 72: 581, 2011. [PMID: 21241354]
19. Montoya RC, Gajra A: Current status of new anticoagulants in the management of venous thromboembolism. *Adv Hematol* 2012: 856341, 2012. [PMID: 22496694]
20. Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW: Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. *J Med Toxicol* 7: 281, 2011. [PMID: 21887485]
21. Kazmi RS, Lwaleed BA: New anticoagulants: how to deal with treatment failure and bleeding complications. *Br J Clin Pharmacol* 72: 593, 2011. [PMID: 21752066]
22. Ghanny S, Warkentin TE, Crowther MA: Reversing anticoagulant therapy. *Curr Drug Discov Technol* 9: 143, 2012. [PMID: 22023256]
23. Levi M, Eerenberg E, Kamphuisen PW: Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. *J Thromb Haemost* 9: 1705, 2011. [PMID: 21729240]
24. Toschi V, Lettino M: Inhibitors of propagation of coagulation: factors V and X. *Br J Clin Pharmacol* 72: 563, 2011. [PMID: 21545479]
25. Weitz JI, Eikelboom JW, Samama MM: New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl.): e120S, 2012. [PMID: 22315258]
26. Patel M, Hellkamp A, Lokhnygina Y, et al: Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial. Published online April 25, 2012. Available at: <http://circ.ahajournals.org/content/early/2012/04/24/CIR.0b013e31825b02ed.full.pdf>. Accessed on June 17, 2012.
27. Eerenberg ES, Kamphuisen PW, Sijkens MK, et al: Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. A randomized, placebo-controlled, crossover study in health subjects. *Circulation* 124: 1573, 2011. [PMID: 21900088]
28. Gray E, Mulloy B, Barrowcliffe TW: Heparin and low-molecular-weight heparin. *Thromb Haemost* 99: 807, 2008. [PMID: 18449410]
29. Garcia DA, Baglin TP, Weitz JI, Samama MM: Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl.): e24S, 2012. [PMID: 22315264]
30. Alban S: Adverse effects of heparin. *Handb Exp Pharmacol* 207: 211, 2012 [PMID: 22566227]
31. Linkins LA, Dans AL, Moores LK, et al: Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl.): e495S, 2012. [PMID: 22315270]
32. Warkentin TE: Agents for the treatment of heparin-induced thrombocytopenia. *Hematol Oncol Clin North Am* 24: 755, 2010. [PMID: 20659659]
33. Elmer J, Wittels KA: Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature. *Transfus Med* 22: 108, 2012. [PMID: 22171588]
34. Nagler M, Haslauer M, Willemin WA: Fondaparinux: data on efficacy and safety in special situations. *Thromb Res* 129: 407, 2012. [PMID: 22133273]
35. Van De Car DA, Rao SV, Ohman EM: Bivalirudin: a review of the pharmacology and clinical application. *Expert Rev Cardiovasc Ther* 8: 1673, 2010. [PMID: 21108549]
36. Abdel-Wahab M, Richardt G: Safety of bivalirudin in patients with coronary artery disease. *Expert Opin Drug Saf* 11: 141, 2012. [PMID: 21999110]
37. Warner TD, Nylander S, Whaling C: Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. *Br J Clin Pharmacol* 72: 619, 2011. [PMID: 21320154]
38. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI: Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl.): e89S, 2012. [PMID: 22315278]
39. Tantry US, Gurbel PA: Current options in oral antiplatelet strategies during percutaneous coronary interventions. *Rev Cardiovasc Med* 12 (Suppl. 1): S4, 2011. [PMID: 22080986]
40. Menozzi A, Lina D, Conte G, Mantovani F, Ardissino D: Antiplatelet therapy in acute coronary syndromes. *Expert Opin Pharmacother* 13: 27, 2012. [PMID: 22149366]
41. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR: Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. *Am Heart J* 162: 115, 2011. [PMID: 21742097]
42. Seshasai SR, Wijesuriya S, Sivakumaran R, et al: Effect of aspirin on vascular and non-vascular outcomes: meta-analysis of randomized controlled trials. *Arch Intern Med* 172: 209, 2012. [PMID: 22231610]
43. Gibson CM, Pride YB, Aylward PE, et al: Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. *J Thromb Thrombolysis* 27: 11, 2009. [PMID: 18695943]
44. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al: Duration of treatment and non-steroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. *Circulation* 123: 2226, 2011. [PMID: 21555710]
45. Pollack CV, Antman EA, Hollander JE: 2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice. *Ann Emerg Med* 52: 344, 2008. [PMID: 18519158]
46. Pollack CV Jr, Braunwald E: 2007 American College of Cardiology/American Heart Association guidelines for the management of patients with unstable angina and non-ST-segment-elevation acute coronary syndrome: implications for emergency department practice. *Ann Emerg Med* 51: 591, 2008. [PMID: 18037193]
47. Kushner FG, Hand M, Smith SC Jr, et al: 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 120: 2271, 2009. [PMID: 19942100]
48. Wijeyeratne YD, Heptinstall S: Anti-platelet therapy: ADP receptor antagonists. *Br J Clin Pharmacol* 72: 647, 2011. [PMID: 21518389]
49. Alonso-Coello P, Bellmunt S, McGorrian C, et al: Antithrombotic therapy in peripheral arterial disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl.): e669S, 2012. [PMID: 22315275]
50. Vandvik PO, Lincoff AM, Gore JM, et al: Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl.): e637S, 2012. [PMID: 22315274]
51. Landsberg MG, O'Donnell MJ, Khatri P, et al: Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl.): e601S, 2012. [PMID: 22315273]
52. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP: CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. *JAMA* 306: 2704, 2011. [PMID: 22203539]

53. Ma TK, Lam YY, Tan VP, Yan BP: Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? *Br J Clin Pharmacol* 72: 697, 2011. [PMID: 21352268]
54. Nawarskas JJ, Snowden SS: Critical appraisal of ticagrelor in the management of acute coronary syndrome. *Ther Clin Risk Manag* 7: 473, 2011. [PMID: 22241994]
55. Wallentin L, Becker RC, Budaj A, et al: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 361: 1045, 2009. [PMID: 19717846]
56. Gressele P, Momi S, Falcinelli E: Anti-platelet therapy: phosphodiesterase inhibitors. *Br J Clin Pharmacol* 72: 634, 2011. [PMID: 21649691]
57. Greenhalgh J, Bagust A, Boland A, et al: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. *Health Technol Assess* 15: 1, 2011. [PMID: 21888837]
58. Squires H, Simpson E, Meng Y, et al: A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. *Health Technol Assess* 15: 1, 2011. [PMID: 22142554]
59. Schneider DJ: Anti-platelet therapy: glycoprotein IIb/IIIa antagonists. *Br J Clin Pharmacol* 72: 672, 2011. [PMID: 21906121]
60. Anderson JL, Adams CD, Antman EM, et al: 2011 ACCF/AHA focused update incorporated into the 2007 ACC/AHA guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 123: e426, 2011. [PMID: 21444888]
61. Friedland S, Eisenberg MJ, Shimony A: Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome. *Am J Cardiol* 108: 1244, 2011. [PMID: 22000626]
62. Giugliano RP, White JA, Bode C, et al: Early versus delayed, provisional eptifibatide in acute coronary syndromes. *N Engl J Med* 360: 2176, 2009. [PMID: 19332455]
63. Peacock WF, Hollander JE, Smalling RW, Bresler MJ: Reperfusion strategies in the emergency treatment of ST-segment elevation myocardial infarction. *Am J Emerg Med* 25: 353, 2007. [PMID: 17349914]
64. Boden WE, Eagle K, Granger CB: Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management option. *J Am Coll Cardiol* 50: 917, 2007. [PMID: 17765117]
65. Kunadian V, Gibson CM: Thrombolytics and myocardial infarction. *Cardiovasc Ther* 30: e81, 2012. [PMID: 21070617]
66. Cannon CP: Thrombolysis medication errors: benefits of bolus thrombolytic agents. *Am J Cardiol* 85: 17C, 2000. [PMID: 10793176]
67. Mehta RH, Alexander JH, Van de Werf F, et al: Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. *JAMA* 293: 1746, 2005. [PMID: 15827313]
68. Lansberg MG, Albers GW, Wijman CA: Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. *Cerebrovasc Dis* 24: 1, 2007. [PMID: 17519538]

## ■ USEFUL WEB RESOURCES

- American College of Chest Physicians: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines—[http://chestjournal.chestpubs.org/content/141/2\\_suppl](http://chestjournal.chestpubs.org/content/141/2_suppl)
- American College of Cardiology: Guidelines and Quality Standards—<http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards.aspx>